Explanipedia

Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024–2025 Open

A De Clercq, François Blanquart, Vincent Vieillefond, Benoit Visseaux, Claire Nour Abou Chakra , et al. · 2025

Influenza 2024-2025 season in France was characterized by prolonged duration, unusual co-circulation of all three viruses (A(H1N1)pdm09, A(H3N2), B/Victoria) with several subclades, and substantial healthcare impact. We aimed to investigat…

Community and Hospital‐Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS‐CoV‐2 During the 2023–2024 Season, Lyon, France Open

Cécile Chauvel, Jean‐Sébastien Casalegno, Benoît Visseaux, Vincent Vieillefond, Stéphanie Haim‐Boukozba , et al. · 2025

Influenza, respiratory syncytial virus (RSV) and SARS‐CoV‐2 are among the main respiratory viruses circulating in the population, with a significant burden on public health. While individuals at higher risk are more likely to develop sever…

Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 Open

Esther Kissling, Marine Maurel, Francisco Pozo, Gloria Pérez‐Gimeno, Silke Buda , et al. · 2025

Introduction Influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.…

Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023–2024 Open

Claire Nour Abou Chakra, François Blanquart, Vincent Vieillefond, Vincent Enouf, Benoit Visseaux , et al. · 2025

The epidemiology of respiratory viruses and vaccine effectiveness (VE) in the community are not well described. This study assessed VE against a positive test of influenza (VEf) and SARS-CoV-2 (VECov). Data from networks of community-based…

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025 Open

François Blanquart, Vincent Vieillefond, Benoit Visseaux, Claire Nour Abou Chakra, Marta C. Nunes , et al. · 2025

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-det…

Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024 Open

A Traore, Kelly Charniga, Sophie Grellet, Garance Terpant, Héléna Da Cruz , et al. · 2025

Background Early detection and characterisation of SARS-CoV-2 variants have been and continue to be essential for assessing their public health impact. In August 2023, Santé publique France implemented enhanced surveillance for BA.2.86 and…

COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network Open

Charlotte Lanièce Delaunay, Nuno Verdasca, Susana Monge, Lisa Domegan, Noémie Sève , et al. · 2025

Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies Open

Delphine Planas, Isabelle Staropoli, Cyril Planchais, Emilie Yab, Banujaa Jeyarajah , et al. · 2024

Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 nov…

Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodies Open

Delphine Planas, Isabelle Staropoli, Cyril Planchais, Emilie Yab, Banujaa Jeyarajah , et al. · 2024

First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, two novel mAbs, P…

COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans Open

Charlotte Lanièce Delaunay, Clara Mazagatos, Iván Martínez‐Baz, Gergő Túri, Luise Goerlitz , et al. · 2024

Importance In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns. Objective To estimate the effectiveness of COVID-…

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine Open

Simon B. Gressens, Vincent Enouf, Antoine Créon, Giovanna Melica, François Lemonnier , et al. · 2024

While daratumumab treatment did not lead to a significant reduction in seroprotection rates following influenza vaccination, a booster vaccine injection demonstrated potential benefit for specific strains (A-H3N2) in patients undergoing da…

Hybrid humoral immune response of Pacific Islanders to BNT162b2 vaccination and Delta/Omicron infection: a cohort study Open

Catherine Inizan, A. M. Courtot, Chloé Sturmach, Anne-Fleur Griffon, Antoine Biron , et al. · 2024

Summary Background Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination strategies adapted to…

COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022 Open

Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos , et al. · 2024

Background Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1…

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024 Open

Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria Pérez‐Gimeno , et al. · 2024

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 count…

Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study Open

Marine Maurel, Francisco Pozo, Gloria Pérez‐Gimeno, Silke Buda, Noémie Sève , et al. · 2024

Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effect…

Influenza vaccine effectiveness in Europe: Results from the 2022–23 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study Open

Marine Maurel, Francisco Pozo, Gloria Pérez‐Gimeno, Silke Buda, Noémie Sève , et al. · 2023

Influenza A(H3N2) viruses dominated early in the 2022–23 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) …

Investigations into SARS-CoV-2 and other coronaviruses on mink farms in France late in the first year of the COVID-19 pandemic Open

Marine Wasniewski, Franck Boué, Céline Richomme, Etienne Simon‐Lorière, Sylvie van der Werf , et al. · 2023

Soon after the beginning of the COVID-19 pandemic in early 2020, the Betacoronavirus SARS-CoV-2 infection of several mink farms breeding American minks ( Neovison vison ) for fur was detected in various European countries. The risk of a ne…

Emergence and evolution of the Omicron SARS-CoV-2 variant in the island of Martinique Open

Gwladys Nadia Gbaguidi, L. Aubert, Justine Schaeffer, L. Fagour, A. Dubremetz , et al. · 2023

Investigations on SARS-CoV-2 and other coronaviruses in mink farms in France at the end of the first year of COVID-19 pandemic Open

Marine Wasniewski, Franck Boué, Céline Richomme, Etienne Simon‐Lorière, Sylvie van der Werf , et al. · 2023

Soon after the beginning of the COVID-19 pandemic in early 2020, the Betacoronavirus SARS-CoV-2 infection of several mink farms breeding American minks ( Neovison vison ) for fur was detected in several countries of Europe. The risk of a n…

Capturing SARS-CoV-2 from patient samples with low viral abundance: a comparative analysis Open

Juliana Pipoli da Fonseca, Étienne Kornobis, Élodie Turc, Vincent Enouf, Laure Lemée , et al. · 2022

Since the beginning of the SARS-CoV-2 coronavirus pandemic, genome sequencing is essential to monitor viral mutations over time and by territory. This need for complete genetic information is further reinforced by the rapid spread of varia…

Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults Open

Juliette Patrier, Khanh Villageois-Tran, Piotr Szychowiak, Stéphane Ruckly, Rémi Gschwind , et al. · 2022

Background The composition of the digestive microbiota may be associated with outcome and infections in patients admitted to the intensive care unit (ICU). The dominance by opportunistic pathogens (such as Enterococcus ) has been associate…

Dynamics of SARS-CoV-2 lineages in French Guiana in 2020–2021: 4 epidemic waves with cross-influences from Europe and South America Open

Alexandra Miliu, Anne Lavergne, Tiphanie Succo, Claire Laizé, Audrey Andrieu , et al. · 2022

Differences in HADS and SF-36 scores 1 year after critical illness in COVID-19 patients Open

Roberta T. Tallarico, Benjamin Deniau, Nicholas Fong, Jade Ghosn, Matthieu Legrand , et al. · 2022

Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020–2021 and 2021–2022 seasons Open

Sophie Vaux, Delphine Viriot, Cécile Forgeot, Isabelle Pontais, Y. Savitch , et al. · 2022

Capturing SARS-CoV-2 from patient samples with low viral abundance: a comparative analysis Open

Juliana Pipoli da Fonseca, Étienne Kornobis, Élodie Turc, Vincent Enouf, Laure Lemée , et al. · 2022

Since the beginning of the SARS-CoV-2 coronavirus pandemic, genome sequencing is essential to monitor viral mutations over time and by territory. This need for complete genetic information is further reinforced by the rapid spread of varia…

Rapid characterization of a Delta-Omicron SARS-CoV-2 recombinant detected in Europe Open

Etienne Simon‐Lorière, Xavier Montagutelli, Frédéric Lemoine, Flora Donati, Franck Touret , et al. · 2022

Recombination is a crucial process in the evolution of many organisms. Although the evolutionary reasons behind its occurrence in RNA viruses are debated, this phenomenon has been associated with major epidemiological events such as virus …

First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022 Open

Anna Maisa, Guillaume Spaccaferri, Pierre‐Edouard Fournier, Justine Schaeffer, J. Deniau , et al. · 2022

Our results confirm a mild clinical presentation among the first Omicron cases detected in France and highlight the importance for the national COVID-19 surveillance system to quickly detect and adapt to the emergence of a new variant.

One Health Genomic Surveillance Reveals Multiple Cross-Reservoirs Transmission Events of Extended-Spectrum β-Lactamase-Producing <i>Escherichia Coli</i> in a Rural Area of Madagascar Open

Noellie Gay, Mamitina Alain Noah Rabenandrasana, Harielle Prisca Panandiniaina, Marie Florence Rakotoninidrina, Ilo Tsimok’Haja Ramahatafandry , et al. · 2022

Early phylodynamics analysis of the COVID-19 epidemic in France Open

Gonché Danesh, Baptiste Elie, Yannis Michalakis, Mircea T. Sofonea, Antonin Bal , et al. · 2021

France was one of the first countries to be reached by the COVID-19 pandemic. Here, we analyse 196 SARS-Cov-2 genomes collected between Jan 24 and Mar 24 2020, and perform a phylodynamics analysis. In particular, we analyse the doubling ti…

Antibody escape and global spread of SARS-CoV-2 lineage A.27 Open

Tamara Kaleta, Lisa Kern, Samuel L. Hong, Martin Hölzer, Georg Kochs , et al. · 2021

In spring 2021, an increasing number of infections was observed caused by the hitherto rarely described SARS-CoV-2 variant A.27 in south-west Germany. From December 2020 to June 2021 this lineage has been detected in 31 countries. Phylogeo…

Vincent Enouf YOU? Author Swipe